COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Descartes-11 Consolidation Treatment in Patients with High Risk Multiple Myeloma who have Residual Disease after Induction Therapy

Protocol No
CARTESIAN-DC11B-HR-MM
Principal Investigator
Binod Dhakal
Phase
II
Summary
The study will explore whether a cell therapy called Descartes-11 provides any benefit in subjects with MM who have high-risk disease and still have disease left over after a first course of standard therapy
Description
Descartes-11 Consolidation Tx in Pts with HR-MM who have Residual Disease after Induction Therapy
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL